Previous 10 | Next 10 |
2023-10-12 16:38:06 ET Shares of Akero Therapeutics (NASDAQ: AKRO) were down more than 70% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence . The healthcare stock closed last week at $50.33, then hit a 52-week low of $14.0...
2023-10-10 15:58:09 ET More on Akero Akero Therapeutics: Contrarian Buy Opportunity As Stock Tanks On 'NASH Dash' Data Akero Therapeutics: An Assessment Biggest stock movers today: Coherent, Truist Financial, Akero Therapeutics and more Akero plummets after m...
2023-10-10 13:28:32 ET Summary Akero Therapeutics' share price is tanking after biotech's NASH drug fails to meet its primary endpoint in a Phase 2B study. Despite the setback, AKRO stock is still trading higher than it was in September 2022, before another Phase 2 study succeeded...
2023-10-10 13:10:42 ET More on 5E Advanced Materials 5E Advanced Materials, Inc. (FEAM) Q4 2023 Earnings Call Transcript 5E Advanced Materials hires new contractors to complete small scale boron facility Seeking Alpha’s Quant Rating on 5E Advanced Materials ...
2023-10-10 11:44:11 ET Shares of Akero Therapeutics (NASDAQ: AKRO) were crashing 66.5% lower as of 11:09 a.m. ET on Tuesday. The steep decline came after the company announced interim results from a phase 2b clinical study evaluating efruxifermin (EFX) in treating patients with comp...
2023-10-10 11:12:01 ET Akero Therapeutics Inc (NASDAQ: AKRO) crashed more than 65% this morning after reporting interim results of SYMMETRY – a Phase 2b study of its non-alcoholic steatohepatitis (NASH) candidate. Akero Therapeutics’ EFX failed a key test On Tuesda...
2023-10-10 10:00:01 ET More on Health Care Select Sector SPDR Citi turns cautious on pharmaceuticals and biotech BofA Securities: Which small cap non-earner stocks to avoid Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR For further deta...
2023-10-10 08:23:35 ET More on Longeveron Longeveron: Alzheimer's Phase 2 Data Around The Corner Longeveron Inc. (LGVN) Q2 2023 Earnings Call Transcript Longeveron falls after mid-stage data for Alzheimer’s candidate Longeveron announces pricing for ri...
2023-10-10 07:35:13 ET More on Akero Akero Therapeutics: An Assessment Biggest stock movers today: Hyatt Hotels, PagerDuty and more Cantor starts Akero at buy, bullish on upcoming data for NASH drug Seeking Alpha’s Quant Rating on Akero Therapeutics ...
22% (28mg EFX) and 24% (50mg EFX) of patients experienced at least a one-stage improvement in liver fibrosis with no worsening of NASH by week 36, compared to 14% for placebo 4% of patients in each EFX dose group experienced a three- or two-stage reversal of fibrosis with no worsening o...
News, Short Squeeze, Breakout and More Instantly...
Akero Therapeutics Inc. Company Name:
AKRO Stock Symbol:
NYSE Market:
Akero Therapeutics Inc. Website:
2024-07-09 15:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 10:00:04 ET Edward Nash from Canaccord Genuity issued a price target of $56.00 for AKRO on 2024-06-12 07:44:00. The adjusted price target was set to $56.00. At the time of the announcement, AKRO was trading at $23.43. The overall price target consensus is at $...
SAN DIEGO, CA / ACCESSWIRE / June 11, 2024 / Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Akero Therapeutics, Inc. (NASDAQ:AKRO) common stock between September 13, 2022 and October 9, 2023, all dates inclusive (the...